Advertisement

Chinese Science Bulletin

, Volume 55, Issue 34, pp 3922–3928 | Cite as

Reactive oxygen species involved in sulforaphane-induced STAT3 inactivation and apoptosis in DU145 prostate cancer cells

  • Wonil Koh
  • Kwang Seok Ahn
  • Soo-Jin Jeong
  • Hyo-Jung Lee
  • Minseok Kim
  • Hyo-Jeong Lee
  • Eun-Ok Lee
  • Sung-Hoon Kim
Article Medical Cell Biology

Abstract

Signal transducer and activator of transcription factor 3 (STAT3) is a transcription factor that regulates various cellular processes such as proliferation, survival and angiogenesis in cancer cells. In the present study, we investigated the mechanisms whereby isothiocyanate sulforaphane (SFN) suppresses STAT3 activation in DU145 prostate cancer cells. SFN significantly inhibited SFN-inhibited STAT3 phosphorylation at Tyr705 as well as the deoxyribonucleic acid (DNA) binding capability in electrophoresis mobility shift assay (EMSA) in time- and concentration-dependent manner. SFN also abrogated the Janus activated kinase 2 (JAK2) phosphoraylation. In addition, SFN down-regulated STAT3-related gene products including Bcl-2, Bcl-xL, and cyclin D1 and vascular endothelial growth factor (VEGF), and inhibited the proliferation and induced apoptosis. Moreover, SFN mediated reactive oxygen species (ROS) production at the early time. Overall, these results demonstrate that ROS generation may be involved in the inhibition of JAK2/STAT3 activation and apoptosis in DU145 cells.

Keywords

sulforaphane STAT3 apoptosis reactive oxygen species DU145 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Talalay P, Fahey J W, Healy Z R, et al. Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc Natl Acad Sci USA, 2007, 104: 17500–17505CrossRefGoogle Scholar
  2. 2.
    Innamorato N G, Rojo A I, Garcia-Yague A J, et al. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol, 2008, 181: 680–689Google Scholar
  3. 3.
    Angeloni C, Leoncini E, Malaguti M, et al. Modulation of phase II enzymes by sulforaphane: Implications for its cardioprotective potential. J Agric Food Chem, 2009, 57: 5615–5622CrossRefGoogle Scholar
  4. 4.
    Zakkar M, van der Heiden K, Luong le A, et al. Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol, 2009, 29: 1851–1857CrossRefGoogle Scholar
  5. 5.
    Song M Y, Kim E K, Moon W S, et al. Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway. Toxicol Appl Pharmacol, 2009, 235: 57–67CrossRefGoogle Scholar
  6. 6.
    Shen G, Xu C, Chen C, et al. p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol, 2006, 57: 317–327CrossRefGoogle Scholar
  7. 7.
    Pappa G, Lichtenberg M, Iori R, et al. Comparison of growth inhibition profiles and mechanisms of apoptosis induction in human colon cancer cell lines by isothiocyanates and indoles from Brassicaceae. Mutat Res, 2006, 599: 76–87Google Scholar
  8. 8.
    Dickinson S E, Melton T F, Olson E R, et al. Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: Implications for chemoprevention of UVB-induced skin cancer. Cancer Res, 2009, 69: 7103–7110CrossRefGoogle Scholar
  9. 9.
    Xu C, Shen G, Yuan X, et al. ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis, 2006, 27: 437–445CrossRefGoogle Scholar
  10. 10.
    Choi S, Lew K L, Xiao H, et al. D,L-sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis, 2007, 28: 151–162CrossRefGoogle Scholar
  11. 11.
    Herman-Antosiewicz A, Xiao H, Lew K L, et al. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line. Mol Cancer Ther, 2007, 6: 1673–1681CrossRefGoogle Scholar
  12. 12.
    Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res, 2007, 635: 90–104CrossRefGoogle Scholar
  13. 13.
    Thimmulappa R K, Mai K H, Srisuma S, et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res, 2002, 62: 5196–5203Google Scholar
  14. 14.
    Yoon H Y, Kang N I, Lee H K, et al. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol, 2008, 75: 2214–2223CrossRefGoogle Scholar
  15. 15.
    Myzak M C, Karplus P A, Chung F L, et al. A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res, 2004, 64: 5767–5774CrossRefGoogle Scholar
  16. 16.
    Schindler C, Shuai K, Prezioso V R, et al. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 1992, 257: 809–813CrossRefGoogle Scholar
  17. 17.
    Niu G, Wright K L, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 2002, 21: 2000–2008CrossRefGoogle Scholar
  18. 18.
    Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med, 2004, 10: 48–54CrossRefGoogle Scholar
  19. 19.
    Wang Y, Ma X, Yan S, et al. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells. Cancer Res, 2009, 69: 7302–7310CrossRefGoogle Scholar
  20. 20.
    Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer, 2004, 4: 97–105CrossRefGoogle Scholar
  21. 21.
    Gao S P, Mark K G, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest, 2007, 117: 3846–3856CrossRefGoogle Scholar
  22. 22.
    Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet, 2009, 41: 450–454CrossRefGoogle Scholar
  23. 23.
    Hu H, Lee H J, Jiang C, et al. Penta-1,2,3,4,6-O-galloyl-beta-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo. Mol Cancer Ther, 2008, 7: 2681–2691CrossRefGoogle Scholar
  24. 24.
    Ren Z, Schaefer T S. ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem, 2002, 277: 38486–38493CrossRefGoogle Scholar
  25. 25.
    Ihle J N. STATs: Signal transducers and activators of transcription. Cell, 1996, 84: 331–334CrossRefGoogle Scholar
  26. 26.
    Lo R K, Cheung H, Wong Y H. Constitutively active Galpha16 stimulates STAT3 via a c-Src/JAK- and ERK-dependent mechanism. J Biol Chem, 2003, 278: 52154–52165CrossRefGoogle Scholar
  27. 27.
    Hahm E R, Singh S V. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells. Cancer Prev Res (Phila Pa), 2010, doi: 10.1158/1940-6207.CAPR-09-0250Google Scholar
  28. 28.
    Ahn K S, Sethi G, Sung B, et al. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res, 2008, 68: 4406–4415CrossRefGoogle Scholar
  29. 29.
    Frank D A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett, 2007, 251: 199–210CrossRefGoogle Scholar
  30. 30.
    Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res, 2003, 9: 316–326Google Scholar
  31. 31.
    Brender C, Nielsen M, Kaltoft K, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood, 2001, 97: 1056–1062CrossRefGoogle Scholar
  32. 32.
    Lou W, Ni Z, Dyer K, et al. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 2000, 42: 239–242CrossRefGoogle Scholar
  33. 33.
    Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer, 2009, 9: 798–809CrossRefGoogle Scholar
  34. 34.
    Kunnumakkara A B, Nair A S, Sung B, et al. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res, 2009, 7: 118–128CrossRefGoogle Scholar
  35. 35.
    Nagata M. Inflammatory cells and oxygen radicals. Curr Drug Targets Inflamm Allergy, 2005, 4: 503–504CrossRefGoogle Scholar
  36. 36.
    Wang C C, Chiang Y M, Sung S C, et al. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.iS2 cells. Cancer Lett, 2008, 259: 82–98CrossRefGoogle Scholar
  37. 37.
    Cho S D, Li G, Hu H, et al. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer, 2005, 52: 213–224CrossRefGoogle Scholar
  38. 38.
    Singh S V, Srivastava S K, Choi S, et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem, 2005, 280: 19911–19924CrossRefGoogle Scholar
  39. 39.
    Ferlay J, Bray F, Pisani P, et al. IARC CancerBase No. 5. Lyon: IARC Press, 2004Google Scholar
  40. 40.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2009, 59: 225–249CrossRefGoogle Scholar
  41. 41.
    Berthold D R, Sternberg C N, Tannock I F. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol, 2005, 23: 8247–8252CrossRefGoogle Scholar
  42. 42.
    Canene-Adams K, Lindshield B L, Wang S, et al. Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res, 2007, 67: 836–843CrossRefGoogle Scholar
  43. 43.
    Myzak M C, Dashwood W M, Orner G A, et al. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J, 2006, 20: 506–508Google Scholar
  44. 44.
    Hutzen B, Willis W, Jones S, et al. Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int, 2009, 9: 24CrossRefGoogle Scholar
  45. 45.
    O’shea J J, Gadina M, Schreiber R D. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell, 2002, 109(Suppl): S121–CrossRefGoogle Scholar
  46. 46.
    Alvarez J V, Febbo P G, Ramaswamy S, et al. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res, 2005, 65: 5054–5062CrossRefGoogle Scholar
  47. 47.
    Hanahan D, Weinberg R A. The hallmarks of cancer. Cell, 2000, 100: 57–70CrossRefGoogle Scholar
  48. 48.
    Shankar S, Ganapathy S, Srivastava R K. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res, 2008, 14: 6855–6866CrossRefGoogle Scholar
  49. 49.
    Wang X, Sharma R K, Sikka S C, et al. Oxidative stress is associated with increased apoptosis leading to spermatozoa DNA damage in patients with male factor infertility. Fertil Steril, 2003, 80: 531–535CrossRefGoogle Scholar
  50. 50.
    Orsucci D, Mancuso M, Siciliano G. Mitochondria, oxidative stress and PARP-1 network: A new target for neuroprotective effects of tetracyclines? J Physiol, 2008, 586: 2427–2428CrossRefGoogle Scholar
  51. 51.
    Gong A, He M, Krishna Vanaja D, et al. Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res, 2009, 53: 878–886CrossRefGoogle Scholar

Copyright information

© Science China Press and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Wonil Koh
    • 1
  • Kwang Seok Ahn
    • 1
  • Soo-Jin Jeong
    • 1
  • Hyo-Jung Lee
    • 1
  • Minseok Kim
    • 2
  • Hyo-Jeong Lee
    • 1
  • Eun-Ok Lee
    • 1
  • Sung-Hoon Kim
    • 1
  1. 1.College of Oriental MedicineKyung Hee UniversitySeoulRepublic of Korea
  2. 2.College of Dental MedicineTufts UniversityBostonUSA

Personalised recommendations